文献速递炎症性肠病消化道肿瘤与早癌

炎症性肠病与小肠癌风险、临床特征及组织病理学:一项基于人群的研究

Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-07-08

该研究基于丹麦1978—2010年≥16岁人群,通过国家登记链接与病历病理复核识别40例炎症性肠病相关小肠癌。随访241,620人年,克罗恩病小肠腺癌SIR为14.38(95%CI 8.78-22.20),神经内分泌肿瘤SIR为6.83(95%CI 3.13-12.97);溃疡性结肠炎未见显著风险升高。多数患者为中度至重度广泛克罗恩病,腺癌呈现炎症—异型增生—癌途径且无微卫星不稳定。

要点

  • 克罗恩病患者小肠腺癌风险升高,SIR为14.38(95%CI 8.78-22.20)。
  • 克罗恩病患者小肠神经内分泌肿瘤风险升高,SIR为6.83(95%CI 3.13-12.97)。
  • 溃疡性结肠炎患者未发现小肠癌风险显著增加。

核心结论

  • 在丹麦炎症性肠病与小肠癌人群中,克罗恩病患者腺癌和神经内分泌肿瘤风险升高。
  • 多数炎症性肠病相关小肠癌患者为中度至重度广泛炎症性肠病。
  • 腺癌似经炎症—异型增生—癌途径发生,但其分子特征与炎症性肠病相关结直肠腺癌不同。

研究设计与样本

  • 基于人群的研究,纳入1978—2010年丹麦所有≥16岁居民。
  • 通过国家登记链接并复核病历和病理描述,识别40例炎症性肠病相关小肠癌。
  • 风险以标准化发病比(SIR,观察值/期望值)计算,患者特征取自病历,手术标本来自全国医院用于组织病理学和分子分析。

主要发现

  • 随访241,620人年,23例克罗恩病患者发生小肠腺癌,SIR为14.38(95%CI 8.78-22.20)。
  • 9例克罗恩病患者发生神经内分泌肿瘤,SIR为6.83(95%CI 3.13-12.97)。
  • 溃疡性结肠炎患者未发现小肠癌风险显著增加。
  • 多数小肠癌患者为中度至重度克罗恩病,伴小肠和上消化道受累。
  • 小肠腺癌手术标本评估显示从炎症到异型增生再到癌的清晰移行,无肿瘤存在微卫星不稳定证据。

关键数值与推荐

  • 克罗恩病小肠腺癌SIR为14.38(95%CI 8.78-22.20)。
  • 克罗恩病小肠神经内分泌肿瘤SIR为6.83(95%CI 3.13-12.97)。
  • 溃疡性结肠炎患者小肠癌风险未显著增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Inflammatory bowel disease (IBD) may increase risk of small bowel cancer (SBC). However, little is known of the characteristics and features of IBD-SBC, due to a low number of cases worldwide. We performed a population-based study of IBD and SBC to calculate risk and increase our understanding of clinical characteristics and histopathological and molecular features. METHODS: The study population consisted of all individuals aged 16 years or older living in Denmark during 1978-2010. Through linkage between national registers and subsequent scrutiny of medical records and pathology descriptions, we identified 40 cases of IBD-SBC. Risk was calculated by standardized incidence ratio (SIR) (observed/expected); patient characteristics were derived from medical files, and surgery specimens were obtained from hospitals nationwide for histopathological and molecular analyses. RESULTS: During 241,620 person-years of follow-up, 23 patients with Crohn's disease developed small bowel adenocarcinoma (SIR, 14.38; 95% confidence interval, 8.78-22.20) and 9 developed neuroendocrine tumors (SIR, 6.83; 95% confidence interval, 3.13-12.97). No significantly increased risk of SBC was found among patients with ulcerative colitis. Most patients with SBC had moderate-to-severe Crohn's disease with small bowel and upper gastrointestinal involvement. Assessment of surgical specimens of small bowel adenocarcinomas revealed a clear transition from inflammation to dysplasia and cancer, whereas no tumors had evidence of microsatellite instability. CONCLUSIONS: In a population-based study of patients in Denmark with IBD and SBC, we found risk of adenocarcinomas and neuroendocrine tumors to be increased among persons with Crohn's disease. Most patients with IBD-SBC had extensive IBD of moderate-to-severe activity. Adenocarcinomas appeared to develop via an inflammation-dysplasia-carcinoma pathway, but differed from IBD-related colorectal adenocarcinomas in their molecular features.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bojesen RD, Riis LB, Høgdall E, et al. Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study. Clin Gastroenterol Hepatol. 2017. PMID: 28694132. doi:10.1016/j.cgh.2017.06.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。